Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 24Gastrointestinal 6CNS 6Tumor-Agnostic 3Genitourinary 3Other hematologic neoplasm 2Lymphoid 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Myeloid 1Gynecologic 1Classical hematology 1

Conditions

Neoplasm Metastasis 3

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 48Radiotherapy 39Magnetic Resonance Spectroscopy 35pembrolizumab 31Gemcitabine 30Bevacizumab 30Nivolumab 29Carboplatin 29Radiosurgery 27Standard of Care 26Oxaliplatin 26Capecitabine 25Paclitaxel 24Interviews as Topic 24Cisplatin 24Fluorouracil 23Erlotinib Hydrochloride 22Everolimus 19Irinotecan 18Trastuzumab 17Methods 17Exercise 17Docetaxel 17Biopsy 17Cyclophosphamide 16Educational Status 15Sorafenib 14Ipilimumab 14Fluorodeoxyglucose F18 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × neratinib × Tumor-Agnostic × Clear all
NCT05933395 2026-01-20

GERTRUDE

Dartmouth-Hitchcock Medical Center

Phase 2 Recruiting
135 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03065387 2026-01-12

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
93 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06083662 2025-03-18

Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers

Korea University Guro Hospital

Phase 2 Completed
42 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡